Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma

NCT00003641 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT00003641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Completed
Start date
March 25, 1999
Completion date
May 26, 2026
Enrollment
1,150 (actual)
Sites
533

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)